Latest News

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is tau-targeting therapies for Alzheimer disease!

A 12-week, placebo-controlled phase 2 trial found that an oral THC/CBD combination significantly reduced agitation in hospice-eligible patients with Alzheimer disease and other dementias, meeting its primary and key secondary endpoints.

Joey English, MD, Chief Medical Officer of Route 92 Medical, discusses the company's reperfusion platform, the goals of the SUMMIT RISE real-world evidence study, and what vessel-matched catheter technology could mean for acute ischemic stroke care.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending July 24, 2026.

Andrew Lee, MD, PhD, cofounder and CEO of Spot Biosystems, discusses the company's extracellular vesicle platform, the first non-viral delivery of full-length dystrophin in patients with Duchenne muscular dystrophy.

Epilepsy expert Susan Duberstein, MD, explores how multidisciplinary neurocutaneous clinics improve diagnosis, surveillance, care coordination, and long-term outcomes for patients with complex neurocutaneous syndromes.

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Craig A. Erickson, MD. [LISTEN TIME: 23 minutes]

Stephen Williams, PhD, chief scientific officer of Alamar Biosciences, discusses the potential of eMTBR-tau measurement, multiplex biomarker testing, and AI-driven approaches to improve the characterization of Alzheimer disease and its coexisting pathologies.

The submission is backed by phase 3 FoCus trial data showing ALXN1840 tripled copper mobilization and produced significant, sustained neurologic improvement compared with standard of care over 48 weeks.

Spinogenix’s codabakalner, an investigational BK channel modulator, is currently being evaluated in CLARITY, a phase 2b/3 trial for the treatment of patients with Fragile X syndrome.

Ahead of World Brain Day, NeurologyLive explores 5 emerging strategies for preventing neurologic disease, from modifiable dementia risk factors to GLP-1 drugs, sleep science, the gut brain axis, and wearable technology.

A look at where things stand for Fragile X syndrome drug development, covering seven agents across four mechanisms as the field regroups from two recent Phase 3 setbacks.

Brett Morrison, MD, PhD, associate professor at Johns Hopkins University, recaps his PNS 2026 presentation on current and emerging biomarkers in peripheral nerve disease, from neurofilament light chain to muscle MRI and microRNA.